Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics, Inc. - Common Stock
(NQ:
DYN
)
18.55
-0.43 (-2.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
April 11, 2025
Via
Benzinga
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
↗
March 21, 2025
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
Via
Benzinga
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
March 20, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
↗
March 12, 2025
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Via
Benzinga
Looking Into Dyne Therapeutics's Recent Short Interest
↗
October 22, 2024
Via
Benzinga
Peering Into Dyne Therapeutics's Recent Short Interest
↗
September 30, 2024
Via
Benzinga
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
March 20, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
March 16, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
March 11, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
February 14, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
January 21, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
↗
January 10, 2025
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.
Via
Benzinga
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for
January 10, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 09, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
January 08, 2025
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 07, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
October 09, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm
September 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 16, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm
September 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
September 09, 2024
From
Kirby McInerney LLP
Via
Business Wire
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 08, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
September 04, 2024
From
The Schall Law Firm
Via
Business Wire
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
↗
September 03, 2024
Via
Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 03, 2024
Via
Benzinga
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
↗
September 03, 2024
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
